Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 6/2020

20.02.2020 | Original Article

CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies

verfasst von: Ashanty M. Melo, Melissa J. Conroy, Emma K. Foley, Éilis Dockry, Eamon P. Breen, John V. Reynolds, Joanne Lysaght, Derek G. Doherty

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Esophageal and gastric cancers collectively cause over 1.1 million deaths annually and only 20–30% of patients respond favorably to current therapies. Cellular therapies using invariant natural killer T (iNKT) cells are showing promise for patients with other cancers; therefore, we investigated if these cells are altered in esophageal and gastric cancer patients. Flow cytometric analysis of peripheral blood from 139 patients revealed that iNKT cells are depleted from patients with esophageal and gastric adenocarcinoma and esophageal squamous cell carcinoma, both before and after treatment. Interrogation of the KMPlot database of transcriptomic data from 876 gastric cancer patients revealed that low CD1d expression is associated with poor prognosis. These observations suggest that therapies that boost CD1d expression and iNKT cell responses may benefit these patients. However, we found that chemotherapies used for esophageal and gastric cancers have adverse effects on iNKT cells in vitro. Cisplatin caused a significant reduction of CD1d expression by esophageal tumor cell lines. Cisplatin, 5-fluorouracil and carboplatin induced dose-dependent apoptosis in primary lines of iNKT cells and inhibited CD1d-dependent interferon-γ production and cytolytic degranulation by viable iNKT cells. Interestingly, cisplatin increased granzyme B and perforin production and decreased the production of the granzyme B inhibitor PI9, which protects cytotoxic cells from self-damage by granzyme B. Thus, cisplatin-induced apoptosis of iNKT cells may be mediated in part by altering granzyme B and PI9 expression. Our data suggest that iNKT cell-based immunotherapies may benefit patients with gastrointestinal cancers, but may be negatively affected by chemotherapies used for these cancers.
Literatur
2.
Zurück zum Zitat Saba N, El-Rayes B (2015) Esophageal cancer. Prevention, diagnosis and therapy. Springer, Atlanta. https://doi.org/10.1007/978-3-319-20068-2 Saba N, El-Rayes B (2015) Esophageal cancer. Prevention, diagnosis and therapy. Springer, Atlanta. https://​doi.​org/​10.​1007/​978-3-319-20068-2
9.
Zurück zum Zitat Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702–3709PubMed Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702–3709PubMed
11.
Zurück zum Zitat Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T (2009) A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182:2492–2501. https://doi.org/10.4049/jimmunol.0800126 CrossRefPubMed Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T (2009) A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182:2492–2501. https://​doi.​org/​10.​4049/​jimmunol.​0800126 CrossRefPubMed
18.
Zurück zum Zitat Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, O'Farrelly C, Doherty DG (2003) NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 171:1775–1779CrossRefPubMed Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, O'Farrelly C, Doherty DG (2003) NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 171:1775–1779CrossRefPubMed
23.
Zurück zum Zitat Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K, Kojima S, Yasugi T, Kozuma S, Taketani Y (2010) CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol 84:11614–11623. https://doi.org/10.1128/jvi.01053-10 CrossRefPubMedPubMedCentral Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K, Kojima S, Yasugi T, Kozuma S, Taketani Y (2010) CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol 84:11614–11623. https://​doi.​org/​10.​1128/​jvi.​01053-10 CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5(Suppl 6):S3–S6PubMed Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5(Suppl 6):S3–S6PubMed
29.
Zurück zum Zitat Sewell HF, Halbert CF, Robins RA, Galvin A, Chan S, Blamey RW (1993) Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer. Int J Cancer 55:735–738CrossRefPubMed Sewell HF, Halbert CF, Robins RA, Galvin A, Chan S, Blamey RW (1993) Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer. Int J Cancer 55:735–738CrossRefPubMed
38.
Zurück zum Zitat Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA, Briere J, Baglin AC, Cheze S, Bosq J, Ribrag V, Gisselbrecht C, Mounier N, Gaulard P (2007) Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 109:2183–2189. https://doi.org/10.1182/blood-2006-07-033142 CrossRefPubMed Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA, Briere J, Baglin AC, Cheze S, Bosq J, Ribrag V, Gisselbrecht C, Mounier N, Gaulard P (2007) Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 109:2183–2189. https://​doi.​org/​10.​1182/​blood-2006-07-033142 CrossRefPubMed
Metadaten
Titel
CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies
verfasst von
Ashanty M. Melo
Melissa J. Conroy
Emma K. Foley
Éilis Dockry
Eamon P. Breen
John V. Reynolds
Joanne Lysaght
Derek G. Doherty
Publikationsdatum
20.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 6/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02514-x

Weitere Artikel der Ausgabe 6/2020

Cancer Immunology, Immunotherapy 6/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.